Detection of prostate-specific antigen coupled to immunoglobulin M in prostate cancer patients

Abstract Background : Several reports indicate that the main biomarkers for liver and colorectal cancer circulating in the blood stream associate with immunoglobulin M (IgM) to form stable complexes that show increased diagnostic relevance compared to circulating free biomarkers. Methods : To furthe...

Full description

Saved in:
Bibliographic Details
Published in:Cancer detection and prevention 2007-01, Vol.31 (5), p.402-407
Main Authors: Beneduce, Luca, PhD, Prayer-Galetti, Tommaso, MD, Giustinian, Andrea Marcello Grimani, Gallotta, Andrea, PhD, Betto, Giovanni, MD, Pagano, Francesco, MD, Fassina, Giorgio, PhD
Format: Article
Language:English
Subjects:
Age
Biomarkers
Cancer
Cancer diagnosis
Cancer immune surveillance
Colorectal cancer
Epidemiology
Hematology, Oncology and Palliative Medicine
Immunoglobulin M immune complexes
Liver cancer
Men
Multivalent IgM
Natural immunity
Prostate
Prostate cancer
Prostate-specific antigen (PSA)
PSA–IgM
Ultrasonic imaging
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background : Several reports indicate that the main biomarkers for liver and colorectal cancer circulating in the blood stream associate with immunoglobulin M (IgM) to form stable complexes that show increased diagnostic relevance compared to circulating free biomarkers. Methods : To further investigate the association between cancer biomarkers and IgM, we assessed the presence of prostate-specific antigen (PSA) as IgM complexes in sera of patients with prostate cancer (PC) or benign prostatic hyperplasia (BPH) in comparison with PSA measurements. Results : PSA–IgM levels were significantly elevated in 40% (20/50) and 12% (6/51) of PC and BPH patients, respectively, compared to 22% (11/50) and 29% (15/51) of PSA positive patients in the same groups. Detection of cancer markedly increased from 22 to 60% by co-determination of both markers (30/50 patients). Significantly elevated levels of PSA–IgM were found in 13 out of 30 patients affected by PC with a PSA value between 4 and 10 ng/mL and only in 4 out of 34 BPH patients in the same PSA range. Conclusions : The results are the first evidence of the occurrence of PSA–IgM complexes in patients with prostate cancer. The gain achieved in cancer detection by using the combination of PSA and PSA–IgM suggests that PSA–IgM could be a complementary serological marker of prostate cancer.
ISSN:0361-090X
1877-7821
1873-443X
1877-783X
DOI:10.1016/j.cdp.2007.10.005